Information Update: Xigris (drotrecogin alfa) Withdrawn Worldwide
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwire) -- 10/25/11 -- Health Canada is informing Canadians that it is working with Eli Lilly Canada, Inc. to withdraw the drug Xigris (drotrecogin alfa) from the Canadian market, in light of the company's decision to withdraw Xigris from the market worldwide.
Xigris is used solely in hospital intensive care units to treat patients at a high risk of death due to serious complications of a blood infection (called sepsis or septic shock). Sepsis is a serious medical condition involving infection and generalized inflammation. The body's normal response to an infection is to set off a limited chain reaction to fight the infection. In severe sepsis, this systemic immune response becomes overactive and can result in damage to vital body organs, leading to bleeding, organ failure and, in many cases, to death. Xigris is used in serious cases only, in addition to other sepsis treatments.
The withdrawal is in light of a large international clinical trial, known as the PROWESS-SHOCK study that showed no benefit for patients receiving Xigris compared to patients who did not receive it.
Health Canada is working with Eli Lilly Canada, Inc. to facilitate the withdrawal in Canada. Additional information on the withdrawal will be communicated to hospitals as soon as it is available.
Eli Lilly Canada, Inc. has also issued a news release () with information on the recall. Physicians, caregivers or patients with additional questions about Xigris can contact the company directly at 1-800-LillyRx (1-800-545-5979) or .
How to report side effects to health products
To report suspected adverse reaction to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or complete a () and send to us using one of these methods:
Fax: 1-866-678-6789
Internet:
Mail ( ()):
Egalement disponible en francais
Contacts:
Media Inquiries:
Health Canada
(613) 957-2983
Public Inquiries:
(613) 957-2991
1-866 225-0709
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.10.2011 - 07:16 Uhr
Sprache: Deutsch
News-ID 1049495
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
OTTAWA, ONTARIO
Phone:
Kategorie:
Government & Administration
Anmerkungen:
Diese Pressemitteilung wurde bisher 85 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Information Update: Xigris (drotrecogin alfa) Withdrawn Worldwide
"
steht unter der journalistisch-redaktionellen Verantwortung von
Health Canada (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
